Thus, PCSK9 antibodies (alirocumab and evolocumab) as well as small interfering mRNAs that inhibit intracellular synthesis of PCSK9 (inclisiran) are FDA approved drugs for adults with hypercholesterolemia and established or high risk of CVD [195]. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.